CryoPort (NASDAQ:CYRX) Announces Quarterly Earnings Results

CryoPort (NASDAQ:CYRX) posted its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01), Zacks reports. The company had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.13%.

Here are the key takeaways from CryoPort’s conference call:

• Revenue reached $49 million in the second quarter, with Life Sciences Services revenue up 15% year over year, commercial cell and gene therapy support revenue up 9%, and clinical-trial support revenue up 12%.
• Cryoport achieved positive adjusted EBITDA of $400,000, a $1.3 million year-over-year improvement, and generated approximately $5 million of operating cash flow in the first half, supporting management’s path toward sustainable profitability.
• The company’s pipeline remains broad, with 779 clinical trials supported globally, 22 commercial cell and gene therapies, and expectations for 11 potential BLA/MAA filings, five new therapy approvals, and one label or geographic expansion during the remainder of 2026.
• Cryoport reaffirmed its 2026 continuing-operations revenue guidance of $192 million to $196 million rather than raising it, citing geopolitical and macroeconomic uncertainty despite strong underlying demand.
• New growth initiatives—including IntegriCell cryopreservation services, the Fusion 811 freezer, China-based manufacturing, and new supply-chain facilities in Paris and Santa Ana—are expected to expand future capacity, although IntegriCell is not expected to contribute significantly to 2026 revenue.

CryoPort Stock Performance

Shares of NASDAQ CYRX traded up $0.41 during mid-day trading on Friday, hitting $15.12. 1,069,240 shares of the stock were exchanged, compared to its average volume of 609,580. CryoPort has a twelve month low of $7.51 and a twelve month high of $16.89. The stock’s fifty day simple moving average is $15.49 and its two-hundred day simple moving average is $11.92. The company has a market cap of $762.05 million, a P/E ratio of -16.80 and a beta of 1.89.

CryoPort News Summary

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Needham raised its price target to $19 from $15 and reiterated a “buy” rating, implying substantial upside from recent trading levels. The upgrade reflects confidence in CryoPort’s growth outlook and pipeline exposure. Benzinga report
• Positive Sentiment: Second-quarter revenue increased 8% year over year to approximately $49.0 million. Life Sciences Services revenue rose 15%, while BioStorage/BioServices revenue grew 25%, showing accelerating demand in key businesses. CryoPort was supporting 779 clinical trials and 22 commercially approved cell and gene therapies at quarter-end. CryoPort second-quarter results
• Positive Sentiment: Investor confidence has improved alongside CryoPort’s expanding pipeline. Conestoga Capital Advisors highlighted the company in its second-quarter investor letter, providing additional institutional-investor support for the growth story. Investor confidence report
• Neutral Sentiment: Management’s fiscal 2026 revenue guidance of $192 million to $196 million brackets the analyst consensus of $194.2 million, signaling continued growth but no major near-term guidance surprise. Q2 2026 earnings call transcript
• Negative Sentiment: Adjusted quarterly EPS was a loss of $0.20, narrowly below the $0.19 loss expected by analysts. Although the loss improved from $0.29 per share a year earlier, the slight earnings miss and CryoPort’s negative return on equity remain concerns for investors. CryoPort Q2 earnings report

Insider Transactions at CryoPort

In related news, CFO Robert Stefanovich sold 169,427 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the sale, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at $1,787,259.50. This trade represents a 60.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Edward J. Zecchini sold 33,600 shares of CryoPort stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the transaction, the insider owned 109,719 shares of the company’s stock, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 227,641 shares of company stock valued at $3,622,515 in the last three months. 9.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. UBS Group AG increased its stake in shares of CryoPort by 112.7% in the 3rd quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock valued at $12,623,000 after buying an additional 705,649 shares during the period. Millennium Management LLC raised its position in shares of CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of CryoPort by 283.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock valued at $4,970,000 after acquiring an additional 387,440 shares during the period. Mak Capital One LLC lifted its stake in shares of CryoPort by 46.6% during the fourth quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after acquiring an additional 381,063 shares during the period. Finally, Empire Financial Management Company LLC boosted its holdings in CryoPort by 141.8% in the fourth quarter. Empire Financial Management Company LLC now owns 403,861 shares of the company’s stock valued at $3,877,000 after acquiring an additional 236,861 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. KeyCorp upped their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Jefferies Financial Group set a $13.50 price target on CryoPort in a research note on Monday, June 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CryoPort in a research report on Monday. Guggenheim increased their price objective on CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. Finally, BTIG Research lifted their price objective on CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, July 24th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CryoPort has an average rating of “Moderate Buy” and an average price target of $18.00.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.